Subgroup analysis according to the method of ApoA-I measurement showed that ApoA-I levels in the plasma of AD patients in the NR group were significantly lower than those in HCs [SMD = −1.73; 95% CI (−3.10, −0.37); P = 0.013; Table 3]; There was no significant difference in plasma ApoA-I levels between AD patients in the ELISA group compared with HCs [SMD = −0.01; 95% CI (−0.21, 0.19); P = 0.942; Table 3]. The gene discussed is APOA1; the disease is Alzheimer disease.